PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

dexamethasone Side Effects

The reactions most often reported to the FDA for dexamethasone (also sold as Decadron), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

285,895
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 1999 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of dexamethasone come from 285,895 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 285,895 reports to the FDA Adverse Event Reporting System (FAERS) for dexamethasone (Decadron): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

285,895

Reports Mentioning Death

46,323

16.2% of reports — not proof the medicine caused the death

Hospitalizations

109,720

38.4% of reports

Top Indication

Plasma Cell Myeloma

Most Reported Adverse Reactions

FATIGUE
16,525
DIARRHOEA
16,515
PLASMA CELL MYELOMA
13,768
NAUSEA
13,495
PNEUMONIA
13,291
DEATH
13,013
NEUTROPENIA
11,217
PYREXIA
10,596
THROMBOCYTOPENIA
10,251
DYSPNOEA
9,899
ANAEMIA
8,771
FEBRILE NEUTROPENIA
8,704
ASTHENIA
8,523
VOMITING
8,506
NEUROPATHY PERIPHERAL
8,250
RASH
7,965
DISEASE PROGRESSION
7,274
CONSTIPATION
6,711

Who Reports Side Effects

Gender Distribution

Female 122,357 (48%)
Male 129,640 (51%)
Unknown 1,724

Age Distribution

0-17 13,977 (7%)
18-44 21,681 (11%)
45-64 66,529 (34%)
65-74 55,881 (28%)
75+ 38,780 (20%)

Reporting Trend by Year

1999 2025

Reactions in Death Reports

Top reactions reported in 46,323 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 12,975
PLASMA CELL MYELOMA 3,987
PNEUMONIA 3,671
SEPSIS 2,860
THROMBOCYTOPENIA 2,448
DISEASE PROGRESSION 2,444
DIARRHOEA 2,235
NEUTROPENIA 2,070
SEPTIC SHOCK 2,036
FATIGUE 1,934
PYREXIA 1,898
ANAEMIA 1,845
RESPIRATORY FAILURE 1,781
DYSPNOEA 1,771
NAUSEA 1,768
INFECTION 1,612
VOMITING 1,586
MALIGNANT NEOPLASM PROGRESSION 1,561

Reactions in Hospitalization Reports

Top reactions in 109,720 reports where hospitalization was an outcome.

Reaction Reports
PNEUMONIA 9,810
PYREXIA 7,352
DIARRHOEA 7,195
FEBRILE NEUTROPENIA 6,205
NAUSEA 5,825
FATIGUE 5,472
DYSPNOEA 5,461
VOMITING 5,035
ANAEMIA 4,411
THROMBOCYTOPENIA 4,305
ASTHENIA 4,286
NEUTROPENIA 4,191
SEPSIS 3,878
ACUTE KIDNEY INJURY 3,329
DEHYDRATION 3,036
HYPOTENSION 2,895
DECREASED APPETITE 2,816
FALL 2,747

Compare dexamethasone vs abiraterone →

What the FAERS Data Reveals About dexamethasone Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 285,895 voluntary reports linked to dexamethasone and its brand equivalents (Decadron), spanning 1999 through 2025. Of those, 46,323 (16.2%) listed death as an outcome and 109,720 (38.4%) involved hospitalization. The most common indication reported alongside adverse events was Plasma Cell Myeloma.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 48% were female and 51% male; age distribution skews toward 45-64, with 66,529 reports in that bracket. The single most reported reaction is fatigue with 16,525 submissions, followed by diarrhoea and plasma cell myeloma.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.